Abstract:
The use of the single nucleotide polymorphism (SNP) of the CLEC1B gene for the identification of cardiovascular and/or thrombotic disorders or of an increased risk for developing cardiovascular and/or thrombotic disorders in a biological sample taken from an individual to be examined; the use of CLEC1B for identifying substances active in preventing and/or treating cardiovascular and/or thrombotic disorders and methods for doing so.
Abstract:
The use of the single nucleotide polymorphism (SNP) of the ADAMTS4 gene for the identification of cardiovascular and peripheral vascular disorders or of an increased risk for developing cardiovascular and peripheral vascular disorders in a biological sample taken from an individual to be examined; the use of ADAMTS4 for identifying substances active in preventing and/or treating cardiovascular and peripheral vascular disorders and methods for doing so.
Abstract:
A method for remote diagnosis and central error evaluation of decentralized electronic devices (1) with an integrated telecommunications device (3) includes the steps of storing information about malfunctions of a decentralized electronic device (1) in a diagnosis memory (6) of the electronic device (1); making a telecommunications connection of the electronic device (1) with a central error evaluation station (7), controlled by the user of the electronic device (1); transmitting error data from the diagnosis memory (6) to the central error evaluation station (7); and evaluating the error data in the central error evaluation station (7).
Abstract:
Radio receivers which scan through a predetermined band of the radio spectrum, in a station-seeking mode, must independently detect whether the currently tuned frequency is the central frequency of the transmitting station and whether this transmitter provides a signal whose strength is sufficient, i.e. whose strength exceeds a predetermined threshold value. Once these two conditions are satisfied, the radio generates a "stop" signal which terminates the station-seeking mode, i.e. keeps the tuning circuit set to the frequency which provided the sufficiently strong signal. The present invention provides an unusually simple way to determine whether these two conditions are satisfied, by using a Finite-Impulse-Response digital filter (2) to extract a d.c. component of the demodulated signal (MPX), for comparison (6) with a predetermined maximum value, and by filtering (10) a field strength signal (FST), for comparison (11) with a predetermined minimum value. When both conditions are satisfied, a simple AND-gate (8) generates the stop-signal.
Abstract:
A circuit arrangement for converting a digital signal of a first frequency into a signal of a second frequency and including an interpolator/decimator is characterized, notably for asynchronous first and second clock signals, in that there is provided at least one multiplexer arrangement which includes a first register which is clocked at the inverted first clock frequency and a second register which is clocked at the second clock frequency, and also includes a multiplexer, the input signal of the multiplexer arrangement being applied to the first register and to a first input of the multiplexer whose second input is coupled to the output of the first register, there also being provided a control circuit which alternately switches the signals applied to the two inputs of the multiplexer to its output in such a manner that at the instants at which this signal is written into the second register a valid signal is always present at the output of the multiplexer.
Abstract:
The present invention refers to a method for the in vitro or in vivo diagnosis of cardiovascular diseases, in particular high blood pressure, stenosis, vessel occlusion and/or other thrombotic events, wherein the nucleotide at position 950 of a nucleic acid coding for the human ARK2 protein or the amino acid at position 298 of the human ARK2 protein of a sample of a person is determined as well as to the use of ARK2 for the development and/or production of a medicament for treating a cardiovascular disease.
Abstract:
The present invention refers to a method of diagnosis of a predisposition to develop thrombotic disease, to test systems and their use for the diagnosis of a predisposition to develop thrombotic disease, to a P2X1 promoter variant and its use for screening for an anti-thrombotic agent, and to methods for identifying an individual that can be prophylactically or therapeutically treated with an anti-thrombotic agent, or for adapting a therapeutic or prophylactic dose of an anti-thrombotic agent.
Abstract:
The present invention refers to a method for the in vitro or in vivo diagnosis of cardiovascular diseases, in particular high blood pressure, stenosis, vessel occlusion and/or other thrombotic events, wherein the nucleotide at position 950 of a nucleic acid coding for the human ARK2 protein or the amino acid at position 298 of the human ARK2 protein of a sample of a person is determined as well as to the use of ARK2 for the development and/or production of a medicament for treating a cardiovascular disease.
Abstract:
The present invention refers to a method for the in vitro diagnosis of thromboembolic and/or coronary heart diseases, wherein the nucleotide at position 470 of a nucleic acid coding for the human EGLN2 protein or the amino acid at position 58 of the human EGLN2 protein of a sample of a person is determined.
Abstract:
The use of the single nucleotide polymorphism (SNP) at position −(97) of the GIP gene for the identification of a cardiovascular disease or of an increased risk for developing a cardiovascular disease in a biological sample taken from an individual to be examined.